Table 2. Correlation of SII with clinicopathologic characteristics by cohort.

Clinical parameter	Primary cohort (N=139)					Validation cohort (N=70)
	SII ≤507 (N=63)	SII >507 (N=76)	χ2	P value		SII ≤507 (N=30)	SII >507 (N=40)	χ2	P value
Sex			0.182	0.669				0.383	0.536
Female	9	9				3	6
Male	54	67				27	34
Age			2.16	0.14				1.228	0.268
≤65	31	28				16	16
>65	32	48				14	24
Surgery type			2.013	0.365				5.624	0.06
Bricker	28	26				12	10
Studer	16	19				10	8
Cutaneous ureterostomy	19	31				8	22
Tumor size			8.88	0.03				9.978	0.002
<3 cm	33	21				16	7
≥3 cm	30	55				14	33
T stage			8.97	0.03				8.353	0.039
Tis-T1	32	27				9	14
T2	15	17				12	7
T3	10	12				3	14
T4	6	20				6	5
N stage			0	0.98				4.55	0.033
N0	53	64				29	30
>N0	10	12				1	10
M stage			0.018	0.893				1.13	0.228
M0	60	72				30	39
M1	3	4				0	1
NLR			41.81	<0.0001				35	<0.001
≤2.3	45	13				24	4
>2.3	18	63				6	36
PLR			36.1	<0.0001				11.433	0.001
≤132.5	52	24				22	13
>132.5	11	52				8	27
CAR			5.42	0.02				6.238	0.013
≤0.2	49	45				25	22
>0.2	14	31				5	18
Blood transfusion			0.018	0.89				0.045	0.832
Yes	25	31				12	15
No	38	45				18	25
Adjuvant chemotherapy			4.078	0.043				4.419	0.036
Yes	20	13				10	5
No	43	63				20	35
Tumor margin			4.62	0.032				4..057	0.044
Yes	5	16				2	10
No	58	60				28	30
Vessel invasion			0.115	0.735				0.326	0.568
Yes	15	20				10	16
No	48	56				20	24
BMI			2.013	0.156				2.312	0.128
≤24	34	50				11	22
>24	29	26				19	18
Diabetes			0.256	0.613				0.02	0.887
Yes	12	12				4	7
No	51	64				26	33
Cardiovascular diseases			0.964	0.326				0.326	0.568
Yes	23	34				10	16
No	40	42				20	24

SII, systemic immune-inflammation index; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; CAR, C-reactive protein/albumin ratio; BMI, body mass index.